Jon Heinrichs | VP
IAVI

Jon Heinrichs is Vice President and head of Discovery Science at IAVI, based in New York City. His responsibilities include advancing broadly neutralizing antibodies for HIV prevention and leading IAVI’s three laboratories, based in La Jolla, CA, Jersey City, NJ, and New Delhi, India. Prior to joining IAVI, Dr. Heinrichs was an Associate Vice President and the Head of Innovation and Emerging Sciences at Sanofi Vaccines in Swiftwater, PA and served as the Global Project Head for nirsevimab, a next generation RSV monoclonal antibody, which was recently licensed in collaboration with AstraZeneca. Prior to joining Sanofi, Dr. Heinrichs headed the Microbial Vaccine Research group at Merck Research Labs where he led a team of scientists developing vaccines for several bacterial pathogens. Dr. Heinrichs previously held positions of increasing responsibility at the biotechnology company MedImmune (now part of AstraZeneca), where he contributed to the identification of vaccine candidates and was involved in research on the efficacy of monoclonal antibodies for the prevention of infectious diseases and the treatment of cancer and inflammatory diseases. Dr. Heinrichs earned his doctoral degree in microbiology and molecular genetics from Rutgers University and the University of Medicine and Dentistry of New Jersey and completed a post-doctoral fellowship in the Laboratory of Bacterial Pathogenesis and Immunology at The Rockefeller University.